<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128488</url>
  </required_header>
  <id_info>
    <org_study_id>2019P001962</org_study_id>
    <secondary_id>1K23HL147799-01</secondary_id>
    <nct_id>NCT04128488</nct_id>
  </id_info>
  <brief_title>Effects of Gender-Affirming Hormone Therapy Among Transgender Women</brief_title>
  <official_title>Effects of Gender-Affirming Hormone Therapy Among Transgender Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Robert Wood Johnson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators plan to evaluate the cardiometabolic effects of initiating&#xD;
      gender-affirming hormone therapy among transgender women with and without HIV. As part of&#xD;
      this study, participants will undergo cardiovascular and metabolic phenotyping within 3&#xD;
      months of starting and after 12 months of gender-affirming hormone therapy. Cardiovascular&#xD;
      phenotyping will include cardiac MRI/MRS imaging to evaluate cardiac function and structure.&#xD;
      Metabolic phenotyping will include oral glucose tolerance testing, abdominal MR imaging to&#xD;
      evaluate visceral adiposity, and whole body, lumbar, and hip DEXA imaging to evaluate fat and&#xD;
      lean body mass as well as bone mineral density, respectively. Traditional markers of CVD risk&#xD;
      as well as immune, hormonal, and coagulation parameters will also be assessed longitudinally.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visceral Adipose Tissue</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Intramyocardial Triglyceride Content on Cardiac MRS</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Function on Cardiac MRI</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Myocardial Fibrosis on Cardiac MRI</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose and Insulin Parameters on Oral Glucose Tolerance Testing</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Density</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hormonal Parameters</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Coagulation Parameters</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hepatic lipid content</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Transgender Women</condition>
  <condition>HIV/AIDS</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Metabolic Disease</condition>
  <condition>Coagulopathy</condition>
  <arm_group>
    <arm_group_label>Transgender women without HIV</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Transgender women with HIV</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Abdominal MR Imaging</intervention_name>
    <description>Imaging to evaluate visceral adipose tissue and hepatic lipid content</description>
    <arm_group_label>Transgender women with HIV</arm_group_label>
    <arm_group_label>Transgender women without HIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI/MRS</intervention_name>
    <description>Imaging to evaluate cardiac function and structure</description>
    <arm_group_label>Transgender women with HIV</arm_group_label>
    <arm_group_label>Transgender women without HIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Glucose Tolerance Testing</intervention_name>
    <description>Blood testing to evaluate changes in glucose and insulin in response to oral glucose load</description>
    <arm_group_label>Transgender women with HIV</arm_group_label>
    <arm_group_label>Transgender women without HIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole Body, Lumbar Spine, and Hip DEXA Imaging</intervention_name>
    <description>Imaging to evaluate fat and lean body mass as well as bone mineral density</description>
    <arm_group_label>Transgender women with HIV</arm_group_label>
    <arm_group_label>Transgender women without HIV</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Transgender Women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  transgender women&#xD;
&#xD;
          -  age ≥16&#xD;
&#xD;
          -  For women with HIV only: on ART therapy for ≥3 months&#xD;
&#xD;
          -  initiation of testosterone suppression with spironolactone or leuprolide and estrogen&#xD;
             therapy with oral 17-β estradiol, transdermal 17β estradiol, sublingual estradiol,&#xD;
             intramuscular estradiol, or subcutaneous estradiol by medical provider&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For women with HIV only: CD4 count&lt;50&#xD;
&#xD;
          -  history of CAD, ACS, ASCVD risk score ≥ 7.5%, LDL-C ≥ 190, or angina (e.g. current&#xD;
             indication for statin use)&#xD;
&#xD;
          -  history of heart failure&#xD;
&#xD;
          -  history of diabetes&#xD;
&#xD;
          -  eGFR &lt; 30 ml/min/1.73m2&#xD;
&#xD;
          -  standard contraindication to MRI, including history of severe allergy to gadolinium or&#xD;
             Dotarem&#xD;
&#xD;
          -  prior orchiectomy&#xD;
&#xD;
          -  gender-affirming hormone therapy for greater than 3 months directly prior to&#xD;
             enrollment&#xD;
&#xD;
          -  current or past anti-platelet therapy or anti-coagulant therapy within the last 6&#xD;
             months •current or past statin therapy within the last 6 months&#xD;
&#xD;
          -  concurrent enrollment in conflicting research study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Transgender Women</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mabel Toribio</last_name>
    <phone>617-724-2826</phone>
    <email>mptoribio@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mabel Toribio</last_name>
      <phone>617-724-2826</phone>
      <email>mptoribio@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Mabel Toribio</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

